{
    "clinical_study": {
        "@rank": "100995", 
        "arm_group": {
            "arm_group_label": "Afatinib"
        }, 
        "brief_summary": {
            "textblock": "In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the\n      Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data\n      for reexamination. Reexamination period is defined by J-PAL. Eight years after approval of a\n      new substance, results of PMS need to be submitted as a part of reexamination dossier to the\n      Japanese regulatory authority, the Ministry of Health, Labour and Welfare (MHLW)."
        }, 
        "brief_title": "Long-term Observation PMS for Afatinib", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Patients with EGFR mutation-positive inoperable or recurrent NSCLC will be included.\n\n        Exclusion criteria:\n\n        - None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "1500"
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02131259", 
            "org_study_id": "1200.181"
        }, 
        "intervention": {
            "arm_group_label": "Afatinib", 
            "description": "20mg -  50mg", 
            "intervention_name": "Afatinib dimaleate", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edogawa,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kisarazu,Chiba", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 8"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Natori,Miyagi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Natori,Miyagi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka,Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ryugasaki,Ibaragi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 6"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ryugasaki,Ibaragi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ryugasaki,Ibaragi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 5"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ryugasaki,Ibaragi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seto,Aichi", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shibukawa,Gunma", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjyuku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Boehringer Ingelheim Investigational Site 10"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post Marketing Surveillance on Long Term Drug Use of GIOTRIF Tablets in Patients With Epidermal Growth Factor Receptor Mutation-positive Inoperable or Recurrent Non-small Cell Lung Cancer.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary safety endpoint is incidence of adverse drug reactions", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02131259"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Objective overall response based on physician's assessment", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}